NCC Acamedy | NCC Medical Showcases Innovative IONM Solutions at the 2025 "Medical Device Gala" to Launch the 2026 NeuGuard Track

NeuGuard Track · Win-Win Collaboration Driven by Sci-Tech Innovation

     As a special invited roadshow enterprise of this conference, NCC Medical fully demonstrated its profound accumulation and innovative achievements in the field of neuroelectrophysiology with the theme of "NeuGuard Track, Rapid Admission and Jointly Exploring the Blue Ocean".

     On our booth, NCC Medical showcased our key investment-promotion products for 2026, including the Intraoperative Neuromonitoring (IONM) System, Wireless Surface EMG System, and Wireless Multi-Channel Sleep Monitoring System and Consumables. Centering on the integrated “Device + Consumables + Software + Service” solution, these products cover multiple application scenarios such as orthopedics, neurosurgery, rehabilitation medicine and sleep medicine, highlighting the company’s comprehensive strength in the fields of intraoperative neural monitoring and rehabilitation & sleep monitoring. The abundant cutting-edge technologies and clinical application cases attracted numerous channel partners to stop for communication and in-depth negotiations.

     Key technical highlights presented to international partners included:

Signal Integrity: Advanced noise-reduction algorithms that ensure stable EMG and MEP (Motor Evoked Potential) recordings even in electronically "noisy" Operating Room environments.

Wireless Versatility: The introduction of the Wireless Surface EMG and Multi-Channel Sleep Monitoring systems, optimizing workflow efficiency in rehabilitation and diagnostic clinics.

Regulatory Compliance: Reiteration of the company’s adherence to ISO 13485 and CE standards, ensuring streamlined market entry and patient safety across European and South American territories.

Investment Promotion Roadshow  · Cooperation Proposition

     During the Investment Promotion Roadshow segment, Marketing Manager of NCC Medical, provided a comprehensive analysis of the broad market space and sustained growth logic of the "neuroprotection market" centered on the "NeuGuard Track". He clearly communicated the cooperation concept of "Joint Investment & Profit Sharing & Risk Sharing", and detailed the Rapid Admission pathways as well as regional investment promotion policies. The on-site atmosphere was lively: many agents scanned the QR code on the spot to join the business communication group, conducted in-depth discussions on product performance, clinical solutions and business policies, and reached multiple intentions for follow-up collaboration — laying a solid foundation for jointly exploring the "neuroprotection" blue ocean market.

Thematic Forum · Industry Insights

     Mr. Mao Shunming, Founder & Chairman of NCC Medical, was invited to attend the thematic forum themed “Keep Pace with the Pulse of the Times — Vitality Amid the Broader Medical Landscape, Reshaping the Core Competitiveness of Medical Devices”, where he shared the company’s 28-year business philosophy and strategic focus with peers in the industry. Faced with the growing pains of the industry brought about by the “Medical Winter”, Mr. Mao put forward a strategic proposition of “Compliant Operations and Intensive Cultivation” to navigate the cycle and build long-term competitiveness. He emphasized that only by adhering to quality and credibility, and committing to continuous innovation and refined operations can the company forge ahead steadily amid changes. This pragmatic yet forward-looking perspective struck a strong chord and inspired in-depth reflection among the attending guests.

     During the industry’s thematic forum, Mr. Mao, Founder and CEO of NCC Medical, addressed the need for long-termism in the medical sector.

"Innovation is not merely about technical specifications; it is about building trust through compliance and clinical value," stated Mr. Mao. "As we move into 2026, NCC Medical is shifting from being a device manufacturer to a comprehensive solution provider. Our focus remains on 'Intensive Cultivation'—optimizing every signal and every partnership to navigate the global market cycle with stability."

     At this grand event, NCC Medical not only demonstrated our leading advantages in the neuroelectrophysiology track, but also mapped out the development blueprint with its extensive partners with an open and win-win attitude. Going forward, the company will continue to be driven by sci-tech innovation, deepen the implementation of clinical value, move forward side by side with partners from all walks of life on the NeuGuard Track, and create new glories for the medical and health industry.

     To further solidify lour global supply chain and regulatory resilience, NCC Medical Group is establishing a Dual-Hub Compliance Framework across Shanghai and Singapore. This strategic initiative ensures that both regional headquarters maintain independent ISO 13485 and CE MDR certifications. This "Dual-Compliance" model not only underscores NCC’s readiness to provide high-standard, compliant IONM solutions to the European and Southeast Asian markets but also guarantees a seamless, de-risked transition for international partners under the most stringent global regulatory frameworks.

About NCC Medical Co.,Ltd

     For 28 years, NCC Medical has focused on tackling key challenges in electrophysiological technology and developing related products. Adhering to the core value of "Commitment,Sincerity,Integrity," the company has continuously launched high-end electrophysiological equipment with independent intellectual property rights, driving the development of the electrophysiology industry. Its independently developed product—the first domestically made neurostimulation monitor specifically designed for intraoperative use in orthopedics and neurosurgery—has achieved a major breakthrough in domestic manufacturing and broken the barrier of reliance on imported equipment. Looking ahead, in the field of intraoperative electrophysiology, NCC Medical aims to strengthen industry-academia-research cooperation with clinical institutions, advance the development of cutting-edge technologies in this field, and provide higher-quality services for patients.

     As a "National-level Specialized, Refined, Differential, and Innovative Little Giant Enterprise" recognized by the Ministry of Industry and Information Technology, NCC Medical has always adhered to independent innovation and lean manufacturing, and built a full-chain independent and controllable system covering core technology R&D to key component production. The company's consumables subsidiary, Shanghai Yingshou Medical Device Co., Ltd., has also been awarded the title of "Shanghai Municipal-level Specialized, Refined, Differential, and Innovative Little Giant Enterprise", which further strengthens the company's leading advantages in the collaborative innovation of equipment and consumables.

     NCC Medical attaches great importance to technological innovation and clinical value. Its independently developed intraoperative  neuromonitoring and 256 high-channel event-related potential digital EEG capable of assisting cognitive diagnosis have both been included in the Shanghai Innovative Medical Devices Catalog . This marks that the products have obtained authoritative recognition in terms of technological advancement, clinical urgency, and quality and safety standards.